<DOC>
	<DOCNO>NCT02236481</DOCNO>
	<brief_summary>The TRACK [ Treatment Rheumatoid Arthritis Comorbidities Kineret ( anakinra ) ] -study : randomize , open-label multicenter study assess efficacy anakinra lower HbA1c ( glycated hemoglobin ) well change DAS28 Rheumatoid Arthritis ( R.A. ) patient type 2 diabetes ( T2D ) Authors : R. Giacomelli , ( A , B ) P. Cipriani ( A ) P. Ruscitti ( A ) behalf TRACK study-group ; ( A ) University L'Aquila , L'Aquila , Italy ; Background : Interleukin-1 ( IL-1 ) play pivotal role R.A. , joint erosion cartilage destruction . ( 1 ) Anakinra ( recombinant form naturally occur IL-1 receptor antagonist ( IL-1Ra ) , block activity IL-1α IL-1β ) show number RCTs ( 2-6 ) effective treatment R.A. , monotherapy , ( 2,4 ) well associate methotrexate ( MTX ) . ( 3,5,6 ) IL-1β play also important role pathogenesis T2D : Glucose show induce IL-1β hypersecretion inflammasome activation , IL-1β induce impairment β-cell secretory function β-cell apoptosis . ( 7 ) In prediabetic subject , expression IL-1Ra induce IL-1β reflect body 's response counterbalance increase IL-1β activity . ( 7 ) Levels IL-1Ra tend rise 6 year diagnosis T2D . ( 8,9 ) IL-1Ra successfully use marker risk develop T2D subject metabolic syndrome . ( 10 ) As clinical proof concept , IL-1 inhibition anakinra patient T2D show improve secretorial function beta-cells well low ratio proinsulin/insulin glycated hemoglobin/hemoglobin significantly , favor glycemic control possibly reduce severity prevalence associate complication disease . ( 11 ) Summarizing , IL-1 inhibition anakinra clinical impact R.A. well T2D . As 6-10 % Italian R.A. patient also T2D , trial aim investigate impact IL-1 inhibition disease . Very recent data also show T2D predictor response anakinra-treatment R.A. patient , ( 12 ) furthermore justifies use anakinra subset R.A. patient . Objectives : [ Primary ] To evaluate change HbA1c baseline , 3 month , 6 month , 1 year last follow 2 year begin ; [ Secondary ] To evaluate efficacy control sign &amp; symptom R.A. , assess remission rate 3 month , 6 month , 1 year follow ( 2 year ) , use evaluation scale disease activity 28 joint , DAS28 SDAI improvement baseline condition time point , accord EULAR response criterion . Methods : 200 patient 28 Italian center active R.A. refractory treatment methotrexate T2D enrol randomize receive either 100mg anakinra daily subcutaneous injection anti-TNF-alfa drug treatment . [ 84 subject require treatment arm reach 90 % power alpha error 0.05 detect mean difference study arm 0.25 percentage point HbA1c . The assumed difference HbA1c rather conservative compare previously publish change T2D patient ( 11 ) . ] Anti-diabetic treatment require unchanged least one month prior enrolment . Patients invite maintain dietary habit lifestyle study period . Further detail view trial website subscription . ( 13 ) References : ( 1 ) Arend &amp; Dayer , Adv . Imm . 1993 ; 54 : 167-227 . ( 2 ) Bresnihan , Arthritis Rheum . 1998 ; 41 : 2196-2204 . ( 3 ) Cohen , Arthritis Rheum . 2002 ; 46 : 614-624 . ( 4 ) Nuki , Arthritis . Rheum . 2002 ; 46 : 2838-2846 . ( 5 ) Cohen , ARD 2004 ; 63 : 1062-1068 . ( 6 ) Cohen , Rheumatology 2004 ; 43 : 704-711 . ( 7 ) Donath , Nat . Rev . Immunol . 2011 ; 11 : 98-107 . ( 8 ) Herder , Diabetes Care 2009 ; 32 : 421-423 . ( 9 ) Carstensen , Diabetes 2010 ; 59 : 1222-1227 . ( 10 ) Luotola , J. Intern . Med . 2011 ; 269 : 322-332 . ( 11 ) Larsen , NEJM 2007 ; 356 : 1517-1526 . ( 12 ) Missler-Karger , EULAR 2013 , Abs . FRI0219 . ( 13 ) http : //www.anakinra-ra-diabetes.org/ Disclosure : This trial receive support Swedish Orphan Biovitrum AB accord Italian law decree 17 December 2004 . ( B ) speaker fee</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Anakinra Patients With Rheumatoid Arthritis Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>male female patient age ≥ 18 year ; previous diagnosis RA criterion American College Rheumatology ( ACR ) / European League Against Rheumatism ( EULAR ) ; Diagnosis Diabetes Mellitus type II accord American Diabetes Association ( ADA ) criterion since least 6 month ; Patients inadequate response previous treatment methotrexate ( determined basis evaluation physician ) ; BMI &lt; 35 Glycated hemoglobin &gt; 7 % &lt; 10 % Minimum score Disease Activity Score28 ( DAS 28 ) &gt; 3.2 For patient previously treat biologic drug , wash treatment least 1 month prior enrollment ; For patient treatment hypoglycemic drug enrollment , change hypoglycemic treatment term type drug dosage , period least 3 month enrolment For patient therapy drug baseline , change term drug administer dosage regimen period least 1 month prior enrollment ; Absence sign symptom related ischemic heart disease Signature write Informed Consent Form . DM2 diagnose since 10 year ; Ongoing Acute infection chronic infection , one following : Increased level Creactive protein &gt; 30 mg / L fever Ongoing treatment antibiotic ; Chronic granulomatous infection ( ie . tuberculosis diagnose radiography laboratory test ) History recurrent infection presence disease induce infection ; Cpeptide value &lt; 0.5 ng / mL ( 0.1665 nmol / L ) presence neutropenia ( WBC &lt; 2000/mm3 ) anemia ( hemoglobin &lt; 11g/dL man 10g/dl woman ) ; presence one contraindication indicate SmPC study drug ( anakinra ) ; presence one contraindication indicate SmPC control drug ( inhibitor TNF alpha ; ATC L04AB ) ; presence one contraindication treatment methotrexate ; previous ischemic attack myocardial infarction ; heart failure NYHA class III IV ; hepatic progressive liver disease ( value ALAT / ASAT increase least two fold compare normal limit ) ; pregnant , woman use contraceptive measure ; breastfeed ; participation another clinical study 6 month randomization ; depressive syndrome serious psychiatric illness , opinion physician , may preclude participation study ; presence know malignancy ; Clinically significant history alcohol abuse drug addiction , , opinion physician , may preclude participation study ; condition , opinion physician , preclude possibility use study drug ( anakinra , Kineret ) control drug ( inhibitor TNF alpha ; L04AB ATC ) compliance SmPC indication ; condition laboratory parameter , opinion physician , preclude subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>